Archives of Disease in Childhood, 47, 794. Nephrogenic diabetes insipidus: effects of 3,5, cyclic-adenosine monophosphate. In view of the evidence that the actions of vasopressin are mediated by the release of adenosine 3,5, cyclic monophosphate ('cyclic-AMP'), the effects of this nucleotide were studied in 3 children with nephrogenic diabetes insipidus (NDI) who were insensitive to vasopressin.
Nephrogenic diabetes insipidus is an hereditary disorder of the kidney characterized by insensitivity to the antidiuretic action of vasopressin (Waring, Kajdi, and Tappan, 1945; Forssman, 1956) . Evidence for the current belief that vasopressin is present in this disorder but that the nephron cannot respond to it has been summarized by Orloff and Burg (1966) . The basis for the failure to respond to vasopressin is unknown.
There is evidence that vasopressin influences the metabolism of the renal medulla in vivo (Jones and Welt, 1967) . Vasopressin is believed to act at cellular level by increasing the formation of adenosine 3,5, cyclic monophosphate ('cyclic-AMP'), which then increases epithelial permeability. Both cyclic-AMP and vasopressin increase the epithelial permeability to water and stimulate active sodium transport in the isolated toad bladder (Orloff and Handler, 1962; Edelman, Petersen, and Gulyassy, 1964) . Both substances increase the permeability to water of isolated rabbit collecting tubules (Grantham and Burg, 1966 Volume 46, 728, 1971. also stimulates production of cyclic-AMP by homogenates of dog kidney (Handler et al., 1965; Brown et al., 1963) .
Cyclic-AMP is present in human urine (Butcher and Sutherland, 1962) and its excretion may increase in response to vasopressin (Pawlson et al., 1970) . Moreover, the administration of cyclic-AMP causes antidiuresis (Levine, 1968; Barraclough and Jones, 1970) . There is thus considerable evidence that vasopressin's actions on the kidneys are mediated by cyclic-AMP. It is possible that in NDI the defect at cellular level involves a failure to generate cyclic-AMP in response to vasopressin. If this were true, then the nucleotide might retain its antidiuretic action thereby offering an approach to therapy. The effects of cyclic-AMP were therefore tested in patients with NDI.
Patients and Methods
The relevant features of the 3 patients studied are shown in Table I . In each patient the diagnosis was established in infancy by the absence of a detectable response to vasopressin after correction of the initial fluid deficit and at a time when the blood urea level was normal. There was no evidence of other defects in tubular function. Case 2 was complicated by dilatation of the urinary tracts. This patient was studied after bilateral ureterostomies had been performed, when the 794 Urine flow fell briefly after each dose of cyclic-AMP in Cases 1 and 3 but did not change appreciably in Case 2 (Fig. 1 to 3) . Urinary osmolality and urinary sodium concentration were not altered detectably by cyclic-AMP (Table II) . Whenever cyclic-AMP reduced urinary flow there were associated falls in osmolal clearance, free water clearance, and in creatinine and urea clearances. All these clearances returned to control levels concurrently with the return of urine flow to control. When cyclic-AMP did not reduce urine flow (Case 2) no significant change occurred in these renal clearances.
Injections of vasopressin (Cases 1 and 3), or of saline (Case 2), were without apparent effect. In the doses used cyclic-AMP always caused a brief tachycardia lasting 2 to 10 minutes. In Case 1, the first dose of cyclic-AMP (40 mg) caused a *The 'control' period values are the means of 3 consecutive 5 to 12 minute collection periods immediately before cyclic-AMP was given. The values shown in each 'C-AMP' period refer to the period in which urine flow was lowest after cyclic-AMP. In every case this was the period immediately after injection of cyclic-AMP. AMP might allow the development of a tubular response to this nucleotide, or that use of the more permeant dibutyryl cyclic-AMP, might produce an antidiuresis resembling that normally caused by vasopressin. rhe present results do not therefore establish firmly that the tubular defect in NDI is after the stage at which cyclic-AMP is formed. Any attempt at circumventing this problem was prevented by the unacceptable circulatory effects already caused by the dosage used and it is concluded that cyclic-AMP has no therapeutic value in NDI.
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